Welgwiyan Secures Tens of Millions in Strategic Financing and Successfully Launches Biotech Chip Production Facility
VCBeat recently learned that Suzhou Wanguiyuan Precision Technology Co., Ltd. (hereinafter referred to as “Wanguiyuan”) has celebrated a double milestone. First,Completed tens of millions of yuan in strategic financing, with existing shareholders Wujiang Dongyun Venture Capital Co., Ltd., Shenzhen Qianhai Sihai New Material Investment Fund Management Co., and Qianrong Holdings continuing to increase their investment. The funds will be primarily used for the construction of an automated production base for microfluidic chips and ongoing R&D, accelerating Wanguiyuan’s expansion of its CDMO business in the global market., secondlyWanguiyuan’s automated biochip production base has successfully commenced operations, ensuring Wanguiyuan’s independent delivery capability.
Wanguiyuan is a comprehensive engineering solutions provider (CDMO) offering one-stop services, including core processes, equipment, and solutions, to enterprises in the fields of in vitro diagnostics, medical devices, life sciences, and biopharmaceuticals.
On June 21, the completion and opening ceremony of Wanguiyuan’s R&D and Intelligent Manufacturing Base for Microfluidic Chips was grandly held.Zhu Yungen, Member of the Party Working Committee and Deputy Director of the Administrative Committee of Wujiang Economic and Technological Development Zone，Mr. Zhang Cangmin, Founder of WanguiyuanYe Xiaoming, Chairman of Qianrong Holdings; Wang Xiaonan, General Manager of Sihai New Materials; Dr. Zhou Peng, Founder of Suzhou Yixin Diagnostics; and Huang Xiaohua, Vice President of Hybio Biological all delivered speeches. All colleagues from Suzhou Wanguiyuan Precision Technology Co., Ltd. attended the ceremony together.
Zhu Yungen, Member of the Party Working Committee and Deputy Director of the Administrative Committee of Wujiang Economic Development Zone, delivered an address
Ms. Ye Xiaoming, Chairman of Qianrong Holdings, Delivers Opening Remarks
Mr. Zhang Cangmin, Founder of Wanguiyuan, Delivers Opening Remarks
On-Site Signing Ceremony
The commencement of operations at Wanguiyuan’s microfluidic chip manufacturing base marks the company’s entry into a new phase, bridging a critical link in the upstream biopharmaceutical supply chain. By establishing three core divisions—customized biochips, medical instruments, and life science automation—Wanguiyuan now provides one-stop services to industry clients.
Wanguiyuan has continued to earn customer recognition and investor favor, primarily due to the following four advantages:
Fully independent and controllable core technologies.Wanguiyuan has accumulated multiple core technologies in the biomedical field, such as micro-volume control technology and sterile environment control technology. By establishing multiple product lines—including overall solutions or technical platforms for microfluidic chips, series of equipment for biological reagent filling and sealing, and automated sterile systems for interventional procedures—it provides end-to-end services from requirement analysis to delivery. To date, Wanguiyuan has obtained 17 granted patents, with 19 patents pending approval and 15 patents under application.
A High-Tech Talent Pool Spanning from Manufacturing to R&D.The core members of its team possess over a decade of experience in the automation industry, control system design, and software design, and have established a mature methodology for various stages of medical device manufacturing production lines. Additionally, these key members bring more than ten years of experience in life sciences projects and the IVD industry, demonstrating keen insight and a profound understanding of life science solutions.
Continuously Improving Delivery Capabilities.Wanguiyuan’s automation equipment business offers customized development based on customer requirements, featuring short delivery lead times and rapid after-sales response. Furthermore, the successful commissioning of its biochip production base will further enhance the company’s CDMO service capabilities for microfluidic chips.
The company has established robust capabilities in automated process and equipment manufacturing, forming a comprehensive CDMO service chain.Wanguiyuan enters the microfluidics sector through proof-of-concept demonstrations, technical services, and automated production lines, while simultaneously establishing medical-grade consumables workshops, microfluidic chip manufacturing facilities, and developing diagnostic instruments. The company will be able to provide customers with comprehensive, end-to-end services spanning product R&D, instrument development, and the production of core chip materials.
The microfluidics market is on the verge of explosive growth, with clear trends emerging. As one of the earliest teams in China engaged in microfluidics-related technologies and processes, the company has established certain technical capabilities and gained recognition from downstream IVD manufacturers. With the successful completion of this round of financing and the smooth commissioning of its biochip production base, Wanguiyuan will leverage its first-mover advantage, seize market opportunities, accelerate the layout of its business lines, and strive to become a comprehensive provider of integrated engineering solutions for one-stop life science services.